Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cholestech's lipid and liver function test launched in the US:

This article was originally published in Clinica

Executive Summary

Hayward, California-based Cholestech is rolling out its Lipid Profile ALT test cassette in the US after the FDA granted CLIA waived status for the product, a test for liver function. The device enables healthcare providers to test a patient's lipid profile and alanine aminotransferase (ALT) levels simultaneously, giving results within five minutes. ALT is the most common marker for liver damage. The test can be performed in the doctor's office lab with just a single fingerstick. It is designed to allow doctors to monitor the patient's use of certain drugs, particularly statins, though lipid and liver monitoring are recommended when using a variety of other prescription drugs. Tests are performed before treatment initiation to establish a baseline level and periodically thereafter to help determine the appropriate therapeutic course of action.

You may also be interested in...



Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel